以岭药业(002603) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥1,549,905,880.51, a decrease of 1.94% compared to ¥1,580,599,501.69 in the same period last year[3] - Net profit attributable to shareholders was ¥288,367,725.11, down 7.18% from ¥310,663,574.03 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥278,845,252.56, reflecting a decline of 9.53% compared to ¥308,231,862.41 in the previous year[3] - The basic earnings per share for the period was ¥0.24, a decrease of 4.00% from ¥0.25 in the same period last year[3] - The diluted earnings per share also stood at ¥0.24, reflecting a 4.00% decline compared to the previous year[3] - The weighted average return on equity was 3.75%, down from 4.26% in the same period last year[3] - The company reported a total of 44,471 common shareholders at the end of the reporting period[6] - Total operating revenue for Q1 2019 was CNY 1,549,905,880.51, a decrease of 1.6% compared to CNY 1,580,599,501.69 in the same period last year[26] - Net profit for Q1 2019 was CNY 288,002,027.14, a decrease of 7.1% from CNY 310,204,164.15 in Q1 2018[27] - The total comprehensive income for the current period was ¥211,833,197.42, compared to ¥175,255,188.97 in the previous period, reflecting overall growth[31] Cash Flow - The net cash flow from operating activities increased significantly by 337.54%, reaching ¥366,645,258.36, compared to a negative cash flow of ¥154,350,991.65 in the same period last year[3] - The cash flow from operating activities generated a net amount of ¥366,645,258.36, a significant recovery from a negative cash flow of -¥154,350,991.65 in the previous period[33] - Total cash inflow from operating activities reached ¥1,245,105,548.63, up from ¥920,506,368.67 year-over-year[35] - The net cash flow from operating activities for the first quarter was ¥246,169,535.31, a significant improvement compared to a net outflow of ¥112,245,827.18 in the same period last year[35] - The company recorded cash inflow from investment recovery of ¥370,000,000.00, significantly higher than ¥150,000,000.00 in the same quarter last year[35] - The company reported a net cash outflow from investing activities of ¥229,362,070.78, contrasting with a net inflow of ¥47,172,483.05 in the prior year[36] - Cash and cash equivalents at the end of the period totaled ¥505,797,516.30, down from ¥521,413,627.50 at the end of the previous year[36] - The company experienced a net increase in cash and cash equivalents of ¥69,837,395.59, compared to a decrease of ¥101,600,859.15 in the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,818,640,991.12, representing a 3.05% increase from ¥8,557,219,469.36 at the end of the previous year[3] - The net assets attributable to shareholders increased by 3.11%, amounting to ¥7,796,588,181.26 compared to ¥7,561,126,276.50 at the end of the previous year[3] - Current assets totaled CNY 5,151,602,635.18, an increase from CNY 4,898,266,265.68 in the previous period, reflecting a growth of approximately 5.16%[19] - Total liabilities amounted to CNY 1,019,883,900.61, up from CNY 993,558,585.64, indicating an increase of about 2.9%[20] - The total assets as of the end of Q1 2019 were CNY 7,943,371,740.72, an increase from CNY 7,775,954,907.69 year-over-year[25] - The total liabilities for Q1 2019 were CNY 799,985,703.16, slightly up from CNY 792,059,501.84 in the previous year[24] - The company's equity increased to CNY 7,143,386,037.56, compared to CNY 6,983,895,405.85 in the same period last year[25] Research and Development - R&D expenses rose by 48.30% to CNY 6,549.18 million, reflecting increased investment in research and development[11] - Research and development expenses increased to CNY 65,491,768.49, up from CNY 44,162,630.28, indicating a focus on innovation[26] - Research and development expenses increased to ¥46,803,297.42, up 54.67% from ¥30,255,168.18 in the previous period, indicating a strong focus on innovation[29] Shareholder Actions - The company repurchased a total of 8,542,600 shares, accounting for 0.71% of total share capital, with a total expenditure of CNY 98,921,930.27[13] - The company plans to use 80% of repurchased shares for employee incentive plans and 20% for capital reduction[12] Financial Management - The company’s financial expenses increased by 155.01% to CNY 134.99 million, mainly due to increased acceptance discounting[11] - The company reported a financial expense of CNY 1,349,886.53, compared to a financial income of CNY -2,453,681.43 in the previous year, indicating a shift in financial management[26] - The financial expenses for the current period were ¥1,275,032.60, a significant improvement from a financial income of -¥2,529,343.66 in the previous period[29] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[30]